Mobilise-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy. The European Innovative Medicines Initiatives funded Mobilise-D project will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease (COPD), Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalized care. Within the framework of Mobilise-D, the University of Zurich leads the conduct of the review work, is responsible for the establishment of the clinical COPD cohort from Switzerland and contributes to statistical analysis, evaluation of results and data availability.

For more information or to participate please visit the project page.